The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Completed
Forest Laboratories
Phase 3
Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to
chronic release of a brain chemical called glutamate. Glutamate helps transmit messages
between nerve cells through interaction with a certain type of receptor
(N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of
excessive glutamate at the receptor (NMDA receptor antagonist).
Tinnitus is commonly referred to as "ringing of the ears" - the perception of sounds in the
absence of an external source of acoustic signals. Tinnitus may represent a severe disease
and symptoms include depression, sleeping difficulties, decreased sound tolerance and hearing
loss. One hypothesis is that tinnitus is caused by an increased activity of NMDA glutamate
and dysfunctional alpha9/alpha10 acetylcholine receptors in the inner ear and central nervous
system. Neramexane may alleviate tinnitus symptoms due to its NMDA and alpha9/alpha10 nACh
receptor blocking activity. The purpose of this study is to assess the safety and efficacy of
Neramexane compared with placebo in patients with subjective tinnitus.
Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus
Completed
Merz Pharmaceuticals GmbH
Phase 2
The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in
the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition,
a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be
included; this subgroup will be analyzed in an exploratory manner only.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
